je.st
news
Tag: janssen
Women Leaders in Waste: Suki Janssen of Athens-Clarke County, Ga.
2019-11-26 09:00:00| Waste Age
The director of Athens-Clarke County Solid Waste Department took a leap of faith in 2002 once she left her teaching career behind to explore a new venture in waste and recycling.
Tags: women
county
leaders
waste
Kramer Acquires Dandruff Shampoo from J&J\'s Janssen
2018-06-26 12:07:00| Happi Breaking News
Established OTC hair treatment product.
Tags: kramer
acquires
janssen
jjs
Medivir Announces That Janssen Has Started a Phase IIa Study to...
2015-10-16 18:07:48| Appliances - Topix.net
Medivir AB today announces that Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies , has started a phase IIa clinical trial to evaluate the combination of simeprevir, odalasvir , and AL-335 in treatment-nai 1 2ve patients with genotype 1 chronic hepatitis C virus infection. This phase IIa study is a randomized, open-label, three-arm study of AL-335, a nucleotide-based HCV NS5B polymerase inhibitor, odalasvir, an HCV NS5A inhibitor and simeprevir, an HCV NS3/4A protease inhibitor.
Janssen, Bayer HealthCare announce results from landmark studies...
2015-09-02 08:58:45| Chemicals - Topix.net
Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS and XANTUS , their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation . The results found the rates and patterns of major bleeding in routine clinical practice were low and generally consistent with those observed in Phase 3 clinical research.
Tags: results
studies
healthcare
announce
Medivir announces that Janssen has started a phase I study to...
2015-08-03 17:02:50| Appliances - Topix.net
Medivir AB today announces that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has started a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir , on the pharmacokinetics of AL-335 in healthy volunteers. This phase I study is an open-label, two-group study of simeprevir, odalasvir, a hepatitis C virus NS5A inhibitor, and of AL-335, a nucleotide-based HCV polymerase inhibitor.